128 related articles for article (PubMed ID: 2069792)
1. The Helsinki Heart Study: central findings and clinical implications.
Huttunen JK; Manninen V; Mänttäri M; Koskinen P; Romo M; Tenkanen L; Heinonen OP; Frick MH
Ann Med; 1991 Apr; 23(2):155-9. PubMed ID: 2069792
[TBL] [Abstract][Full Text] [Related]
2. Relation between baseline lipid and lipoprotein values and the incidence of coronary heart disease in the Helsinki Heart Study.
Manninen V; Huttunen JK; Heinonen OP; Tenkanen L; Frick MH
Am J Cardiol; 1989 May; 63(16):42H-47H. PubMed ID: 2650524
[TBL] [Abstract][Full Text] [Related]
3. Helsinki Heart Study. New perspectives in the prevention of coronary heart disease.
Huttunen JK; Frick MH; Heinonen OP; Heinsalmi P; Manninen V; Mänttäri M; Romo M
Drugs; 1988; 36 Suppl 3():32-6. PubMed ID: 3076118
[TBL] [Abstract][Full Text] [Related]
4. Rationale and design of the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (HIT) for secondary prevention of coronary artery disease in men with low high-density lipoprotein cholesterol and desirable low-density lipoprotein cholesterol.
Rubins HB; Robins SJ; Iwane MK; Boden WE; Elam MB; Fye CL; Gordon DJ; Schaefer EJ; Schectman G; Wittes JT
Am J Cardiol; 1993 Jan; 71(1):45-52. PubMed ID: 8420235
[TBL] [Abstract][Full Text] [Related]
5. Lipoproteins and coronary heart disease in the Helsinki Heart Study.
Mänttäri M; Huttunen JK; Koskinen P; Manninen V; Tenkanen L; Heinonen OP; Frick MH
Eur Heart J; 1990 Dec; 11 Suppl H():26-31. PubMed ID: 2073911
[TBL] [Abstract][Full Text] [Related]
6. Effects of regular and extended-release gemfibrozil on plasma lipoproteins and apolipoproteins in hypercholesterolemic patients with decreased HDL cholesterol levels.
Schaefer EJ; Lamon-Fava S; Cole T; Sprecher DL; Cilla DD; Balagtas CC; Rowan JP; Black DM
Atherosclerosis; 1996 Nov; 127(1):113-22. PubMed ID: 9006811
[TBL] [Abstract][Full Text] [Related]
7. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment.
Manninen V; Tenkanen L; Koskinen P; Huttunen JK; Mänttäri M; Heinonen OP; Frick MH
Circulation; 1992 Jan; 85(1):37-45. PubMed ID: 1728471
[TBL] [Abstract][Full Text] [Related]
8. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.
Frick MH; Elo O; Haapa K; Heinonen OP; Heinsalmi P; Helo P; Huttunen JK; Kaitaniemi P; Koskinen P; Manninen V
N Engl J Med; 1987 Nov; 317(20):1237-45. PubMed ID: 3313041
[TBL] [Abstract][Full Text] [Related]
9. Changes of lipoprotein profile in familial dysbetalipoproteinemia with gemfibrozil.
Zhao SP; Smelt AH; Leuven JA; Vroom TF; van der Laarse A; van 't Hooft FM
Am J Med; 1994 Jan; 96(1):49-56. PubMed ID: 8304363
[TBL] [Abstract][Full Text] [Related]
10. Analyzing of high-density lipoprotein subfractions and low-density lipoprotein subfractions in human serum with anion-exchange chromatography.
Hirowatari Y; Tsunoda Y; Ogura Y; Homma Y
Atherosclerosis; 2009 Jun; 204(2):e52-7. PubMed ID: 19091316
[TBL] [Abstract][Full Text] [Related]
11. Effects of simvastatin, bezafibrate and gemfibrozil on the quantity and composition of plasma lipoproteins.
Nakandakare E; Garcia RC; Rocha JC; Sperotto G; Oliveira HC; Quintão EC
Atherosclerosis; 1990 Dec; 85(2-3):211-7. PubMed ID: 2102085
[TBL] [Abstract][Full Text] [Related]
12. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial.
Robins SJ; Collins D; Wittes JT; Papademetriou V; Deedwania PC; Schaefer EJ; McNamara JR; Kashyap ML; Hershman JM; Wexler LF; Rubins HB;
JAMA; 2001 Mar; 285(12):1585-91. PubMed ID: 11268266
[TBL] [Abstract][Full Text] [Related]
13. Predictive value for coronary heart disease of baseline high-density and low-density lipoprotein cholesterol among Fredrickson type IIa subjects in the Helsinki Heart Study.
Manninen V; Koskinen P; Manttari M; Huttunen JK; Canter D; Frick HM
Am J Cardiol; 1990 Sep; 66(6):24A-27A. PubMed ID: 2392990
[TBL] [Abstract][Full Text] [Related]
14. Gemfibrozil therapy in primary type II hyperlipoproteinemia: effects on lipids, lipoproteins and apolipoproteins.
Lupien PJ; Brun D; Gagné C; Moorjani S; Bielman P; Julien P
Can J Cardiol; 1991; 7(1):27-33. PubMed ID: 2025787
[TBL] [Abstract][Full Text] [Related]
15. [Clinical study of the month. Usefulness of increasing HDL cholesterol in secondary prevention of coronary heart disease: results of the VA-HIT study].
Scheen AJ
Rev Med Liege; 1999 Sep; 54(9):773-5. PubMed ID: 10589275
[TBL] [Abstract][Full Text] [Related]
16. Gemfibrozil prevents major coronary events by increasing HDL-cholesterol and more.
Doggrell SA
Expert Opin Pharmacother; 2001 Jul; 2(7):1187-9. PubMed ID: 11583069
[TBL] [Abstract][Full Text] [Related]
17. Cholesterol Levels of Six Fractionated Serum Lipoproteins and its Relevance to Coronary Heart Disease Risk Scores.
Manita D; Yoshida H; Hirowatari Y
J Atheroscler Thromb; 2017 Sep; 24(9):928-939. PubMed ID: 28025448
[TBL] [Abstract][Full Text] [Related]
18. Effect of honey intake on serum cholesterol, triglycerides and lipoprotein levels in albino rats and potential benefits on risks of coronary heart disease.
Alagwu EA; Okwara JE; Nneli RO; Osim EE
Niger J Physiol Sci; 2011 Dec; 26(2):161-5. PubMed ID: 22547185
[TBL] [Abstract][Full Text] [Related]
19. Rationale for use of non-high-density lipoprotein cholesterol rather than low-density lipoprotein cholesterol as a tool for lipoprotein cholesterol screening and assessment of risk and therapy.
Frost PH; Havel RJ
Am J Cardiol; 1998 Feb; 81(4A):26B-31B. PubMed ID: 9526810
[TBL] [Abstract][Full Text] [Related]
20. Lipoprotein profiling by high performance gel chromatography.
Tallis GA; Shephard MD; Whiting MJ
Clin Chim Acta; 1994 Aug; 228(2):171-9. PubMed ID: 7988033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
